Therapy News and Research

RSS

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

American Shared Hospital Services, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the fourth quarter and 2013.

27 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

Researchers discover new way of giving people sweet dreams

Today psychologist Professor Richard Wiseman from the University of Hertfordshire announces the results of a two-year study into dream control. The experiment shows that it is now possible for people to create their perfect dream, and so wake up feeling especially happy and refreshed.

27 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy - delivered directly through a tumor's blood supply - is working.

27 Mar 2014

Blood-brain barrier following stoke prevents harmful substances entering brain

Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.

27 Mar 2014

BD Micro-Fine Ultra Pen Needle with Pentapoint technology launched in the UK and Ireland

BD (Becton, Dickinson and Company), a leading global medical technology company, announced today the launch in the UK and Ireland of BD Micro-Fine Ultra with 5-bevel needle technology, clinically demonstrated to improve injection comfort for diabetes patients, and enhancing the injection advantages of the current BD Micro-Fine+ Pen Needle.

From BD (Becton, Dickinson and Company) 27 Mar 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

Study points to potential culprit that kills motor neurons in ALS

Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is marked by a cascade of cellular and inflammatory events that weakens and kills vital motor neurons in the brain and spinal cord. The process is complex, involving cells that ordinarily protect the neurons from harm. Now, a new study by scientists in The Research Institute at Nationwide Children's Hospital points to a potential culprit in this good-cell-gone-bad scenario, a key step toward the ultimate goal of developing a treatment.

27 Mar 2014

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.

27 Mar 2014

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

The international guidelines on the drug-based therapy of diabetes mellitus specify which factors need to be taken into account during treatment.

27 Mar 2014

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections.

26 Mar 2014

Emergence of community-acquired infections due to ESBL-producing bacteria on the rise

The emergence of community-acquired infections, such as urinary tract infections (UTI), due to strains resistant to common antibiotics are on the rise, according to Rhode Island Hospital researchers. The study is published online in the journal Antimicrobial Resistance and Infection Control.

26 Mar 2014

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.

26 Mar 2014

Study lays groundwork for PET imaging studies on human Menkes disease

Scientists at the RIKEN Center for Life Science Technologies have used PET imaging to visualize the distribution in the body of copper, which is deregulated in Menkes disease, a genetic disorder, using a mouse model. This study lays the groundwork for PET imaging studies on human Menkes disease patients to identify new therapy options.

26 Mar 2014

New approach could lead to devising alternative tools for cancer therapy

Inducing biological tissue damage with an atmospheric pressure plasma source could open the door to many applications in medicine

26 Mar 2014

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

26 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

Report: Prescription barriers more likely in exchange plans

The analysis by Avalere Health says that consumers who purchased health law coverage are more likely to have to get prior authorization, among other requirements, when filling prescriptions.

26 Mar 2014

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia.

25 Mar 2014

Therapy News and Research

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

Cytrx releases statement in response to two recent lawsuits

Researchers discover new way of giving people sweet dreams

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

Blood-brain barrier following stoke prevents harmful substances entering brain

BD Micro-Fine Ultra Pen Needle with Pentapoint technology launched in the UK and Ireland

New era of lung cancer therapy close to dawning

Study points to potential culprit that kills motor neurons in ALS

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Emergence of community-acquired infections due to ESBL-producing bacteria on the rise

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Study lays groundwork for PET imaging studies on human Menkes disease

New approach could lead to devising alternative tools for cancer therapy

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Report: Prescription barriers more likely in exchange plans

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News